ARCH Venture Partners XII, LLC

ARCH Venture Partners XII, LLC discloses dealings in 5 companies, chiefly Neumora Therapeutics, Inc., Metsera, Inc. and City Therapeutics, Inc. Between 22 September 2023 and 19 October 2026, the trades on record add up to 34 filings.

Purchases make up the whole of the open-market record (24 purchases, €79.0M). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €339k. Of 14 purchases, 14 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 4 purchases with a full 90-day history, the hit rate stands at 75% and the median 90-day move at +51.6%. Past outcomes like these are no guarantee of what comes next.

On 19 October 2026 came the latest disclosure, a transaction in City Therapeutics, Inc. The last purchase on record was published on 19 October 2026, which is 21 days ago. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.